Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01001520 · ClinicalTrials.gov registry record · Phase 2
Neural Substrates in Nicotine Withdrawal
A Phase 2 study, sponsored by University of Pennsylvania.
- Completed
- Registry status
- Phase 2
- Development phase
- 218
- Enrollment target
NCT01001520: Completed Phase 2 study, sponsored by University of Pennsylvania.
NCT01001520 is a Phase 2 study that has completed, run by University of Pennsylvania. The registered enrollment target is 218 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (64% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01001520, a Phase 2 study, has completed, sponsored by University of Pennsylvania.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 218 participants
- Enrollment target
Study Summary
This study will test the hypothesis that a medication called tolcapone (Brand Name: Tasmar) will help reduce cognitive problems that smokers experience when they quit. This study will also determine whether the benefits of this medication differ depending on a smokers' genetic background.
Primary Outcome
Subjects completed two, 11-day study medication periods (one taking active tolcapone; one taking placebo). On Day 8 of each period, after at least 24 hours of smoking abstinence, subjects had an fMRI scan to measure changes in brain activity that occur during a memory test. The subjects completed a commonly used working memory test referred to as the "N-back". This test presented complex geometric figures on a projection screen for 0.5 seconds; each figure is separated by 2.5 seconds of black sc
Interventions
- DRUG Placebo
- DRUG Tolcapone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 218 participants |
| Start Date | 2010-01 |
| Est. Completion | 2012-10 |
| Phase | Phase 2 |
What the finished NCT01001520 record still lists
NCT01001520 is an interventional study that assigns participants to a tested intervention. The registered 218 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (64% higher).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01001520 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01001520 about?
NCT01001520 is a clinical study titled "Neural Substrates in Nicotine Withdrawal". This study will test the hypothesis that a medication called tolcapone (Brand Name: Tasmar) will help reduce cognitive problems that smokers experience when they quit. This study will also determine whether the benefits of this medication differ depending on a smokers' genetic background.
What is the current status of trial NCT01001520?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 218 participants. The study started on 2010-01. Estimated completion is 2012-10.
What interventions are being tested in trial NCT01001520?
The interventions under investigation include: Placebo (DRUG), Tolcapone (DRUG).
Who is sponsoring clinical trial NCT01001520?
This trial is sponsored by University of Pennsylvania, which has 1,423 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01001520's enrollment target sits among peer trials
218 284th of 2000 higher than 1,715 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04693858 · 218 participants · NA
Efficacy Trial of the CALM Intervention
- NCT05909202 · 218 participants · NA
A Nature-Based Virtual Reality (VR) Intervention in Family Caregivers of Allogeneic Hematopoietic Stem Cell Transplant (HSCT) Recipients
- NCT06000761 · 218 participants · NA
Frequent Standardized Oral Care Using Human Milk in the Neonatal Intensive Care Unit
- NCT06249126 · 218 participants · NA
Primary Subtalar Arthrodesis for Calcaneal Fractures
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia